Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EudraCT# 2006-003865-15 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Epratuzumab | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| The primary objective is to continue to gather long term safety data on patients with moderate to severe flaring SLE. |
| Measure | Description | Time Frame |
|---|---|---|
| To continue to assess the efficacy and tolerability of epratuzumab; | ||
| To continue to monitor the plasma concentration and immunogenicity profile of epratuzumab in patients with Lupus; | ||
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anna Barry | UCB Pharma | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Birmingham | Alabama | United States | ||||
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| To continue to assess epratuzumab on Health-related quality of life in lupus patients; |
| To continue to assess disease status as reported by the patient and physician. |
| Tucson |
| Arizona |
| United States |
| Los Angeles | California | United States |
| Upland | California | United States |
| Farmington | Connecticut | United States |
| Washington D.C. | District of Columbia | United States |
| Aventura | Florida | United States |
| Chicago | Illinois | United States |
| Baltimore | Maryland | United States |
| New York | New York | United States |
| Syracuse | New York | United States |
| The Bronx | New York | United States |
| Durham | North Carolina | United States |
| Winston-Salem | North Carolina | United States |
| Gallipolis | Ohio | United States |
| Tulsa | Oklahoma | United States |
| Charleston | South Carolina | United States |
| Dallas | Texas | United States |
| Arlington | Virginia | United States |
| Edmonds | Washington | United States |
| Brussels | Belgium |
| Liège | Belgium |
| Rio de Janeiro | Rio de Janeiro | Brazil |
| Goiânia | Brazil |
| Rio de Janeiro | Brazil |
| São Paulo | Brazil |
| Winnipeg | Manitoba | Canada |
| Hradec Králové | Czechia |
| Olomouc | Czechia |
| Prague | Czechia |
| Paris | France |
| Toulouse | France |
| Erlangen | Germany |
| Heidelberg | Germany |
| Mannheim | Germany |
| München | Germany |
| Debrecen | Hungary |
| Pécs | Hungary |
| Ancona | Italy |
| Brescia | Italy |
| Amsterdam | Netherlands |
| Groningen | Netherlands |
| Leiden | Netherlands |
| Piešťany | Slovakia |
| Barcelona | Spain |
| Madrid | Spain |
| Santander | Spain |
| Seville | Spain |
| Leeds | West Yorkshire | United Kingdom |
| Birmingham | United Kingdom |
| London | United Kingdom |
| Manchester | United Kingdom |
| Newcastle upon Tyne | United Kingdom |
| Sheffield | United Kingdom |
| ID | Term |
|---|---|
| D008180 | Lupus Erythematosus, Systemic |
| ID | Term |
|---|---|
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C448700 | epratuzumab |
Not provided
Not provided
Not provided